Jazz-linked lurbinectedin GI trial posts results; new JZP269 Phase 1 study registered
HonorHealth's Jazz-collaborated lurbinectedin trial in GI cancers with DNA repair mutations reports results, while Jazz registers a first-in-human study of orexin-2 agonist JZP269.
Two items moved this week for Jazz Pharmaceuticals, one as collaborator and one as sole sponsor.
- A Phase II pilot trial of lurbinectedin (Zepzelca, PM01183) in adult patients at least 18 years old with histologically or cytologically confirmed gastrointestinal carcinoma and known or suspected deleterious DNA repair mutations1 has completed, with results first posted. The study, sponsored by HonorHealth Research Institute with Jazz Pharmaceuticals as collaborator, enrolled 8 participants and used a single-group design1, with overall response rate at 12 weeks as the primary outcome measuring antitumor activity1.
- Jazz Pharmaceuticals registered a new Phase 1 study of JZP269, described as an orexin-2 receptor agonist, in healthy participants2, to characterize its safety, tolerability, pharmacokinetics, and pharmacodynamics. The trial, sponsored by Jazz Pharmaceuticals, is an experimental drug versus placebo comparator design2 and plans to enroll 188 participants2, with status listed as not yet recruiting.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.